Skip to main content
Premium Trial:

Request an Annual Quote

Agena Inks MassArray Distribution Deal for Middle East, Africa, Central Asia

NEW YORK — Agena Bioscience said on Wednesday that it has signed an exclusive distribution deal for its MassArray platform and related products in the Middle East, Africa, and Central Asia with Alliance Global.

According to Agena, the deal covers its MassArray mass spectrometry-based platform for genetic variant measurement, genetic testing applications on the system, and certain other products.

Additional terms were not disclosed.

"With their extensive biomedical distribution network, [Alliance Global] is an ideal partner to bring our high-throughput, low-cost, targeted genetic analysis solution to these emerging healthcare markets," Roman Haehn, senior VP of commercial operations at Agena, said in a statement.

Earlier this month, Agena launched a SARS-CoV-2 variant panel that runs on the MassArray system. The San Diego-based company also recently received Emergency Use Authorization from the US Food and Drug Administration for a MassArray SARS-CoV-2 test.

The Scan

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.